John A Wagner Selected Research

N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamide

10/2010	Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
2/2009	Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
1/2009	Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
11/2008	Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John A Wagner Research Topics

Disease

19	Type 2 Diabetes Mellitus (MODY) 03/2016 - 03/2002
14	Dyslipidemias (Dyslipidemia) 01/2018 - 01/2002
10	Neoplasms (Cancer) 02/2015 - 12/2006
9	Flushing 08/2012 - 10/2008
6	Obesity 01/2016 - 11/2008
5	Hepatic Insufficiency 11/2014 - 01/2009
4	Infections 01/2018 - 06/2005
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 06/2011
4	Sleep Initiation and Maintenance Disorders (Insomnia) 08/2016 - 12/2013
4	Hypersensitivity (Allergy) 08/2012 - 06/2002
4	Inflammation (Inflammations) 09/2008 - 01/2002
4	Contact Dermatitis (Eczema, Contact) 03/2008 - 06/2002
3	Renal Insufficiency (Renal Failure) 11/2014 - 10/2006
3	Hypoglycemia (Reactive Hypoglycemia) 08/2006 - 12/2005
2	Body Weight (Weight, Body) 03/2016 - 04/2012
2	Hepatitis C 01/2016 - 03/2013
2	Hypercholesterolemia 01/2014 - 03/2010
2	Osteoporosis 05/2013 - 01/2013
2	Heart Failure 12/2012 - 01/2010
2	Chronic Disease (Chronic Diseases) 06/2011 - 01/2002
2	Injection Site Reaction 02/2011 - 12/2010
2	Disease Progression 12/2010 - 06/2008
2	Nausea 12/2010 - 12/2006
2	Weight Loss (Weight Reduction) 02/2009 - 05/2007
2	Hypertension (High Blood Pressure) 05/2008 - 01/2002
2	Insulin Resistance 03/2004 - 03/2002
1	Celiac Disease (Celiac Sprue) 01/2021
1	Migraine Disorders (Migraine) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Aortic Valve Stenosis (Aortic Stenosis) 01/2017
1	Hallucinations (Hallucination) 08/2016
1	Apnea 01/2016
1	Obstructive Sleep Apnea 01/2016
1	Hypoxia (Hypoxemia) 03/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 03/2015
1	Hot Flashes 09/2014

Drug/Important Bio-Agent (IBA)

15	Sitagliptin Phosphate (Januvia)FDA Link 01/2012 - 12/2005
10	Pharmaceutical PreparationsIBA 08/2016 - 12/2002
10	MK-0524IBA 01/2014 - 01/2009
10	Niacin (Nicotinic Acid)FDA LinkGeneric 08/2012 - 10/2008
7	anacetrapibIBA 01/2018 - 01/2009
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2008
5	Dipeptidyl-Peptidase IV InhibitorsIBA 03/2016 - 01/2006
5	ProstaglandinsIBA 08/2012 - 01/2009
4	Cholesterol Ester Transfer ProteinsIBA 01/2018 - 01/2009
4	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 09/2011 - 12/2005
4	N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA 10/2010 - 11/2008
4	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2006 - 12/2005
3	Orexin Receptor AntagonistsIBA 08/2016 - 03/2015
3	suvorexantIBA 08/2016 - 03/2015
3	ridaforolimusIBA 11/2014 - 07/2012
3	Vorinostat FDA Link 09/2013 - 12/2006
3	Proteins (Proteins, Gene)FDA Link 06/2013 - 03/2004
3	prostaglandin D2 receptorIBA 11/2009 - 04/2009
3	Adenosine Triphosphate (ATP)IBA 09/2008 - 06/2005
3	IncretinsIBA 07/2008 - 11/2006
2	Apolipoproteins AIBA 01/2017 - 06/2013
2	Apoprotein(a) (Apolipoprotein (a))IBA 01/2017 - 06/2013
2	Lipoprotein(a)IBA 01/2017 - 06/2013
2	Hypnotics and Sedatives (Sedatives)IBA 08/2016 - 03/2015
2	2- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA 03/2016 - 01/2016
2	Midazolam (Versed)FDA LinkGeneric 11/2014 - 01/2009
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2014 - 04/2009
2	Cathepsin KIBA 05/2013 - 01/2013
2	odanacatibIBA 05/2013 - 01/2013
2	Warfarin (Coumadin)FDA LinkGeneric 01/2013 - 11/2008
2	TOR Serine-Threonine KinasesIBA 10/2012 - 07/2012
2	LipidsIBA 01/2012 - 10/2008
2	Raltegravir Potassium FDA Link 10/2011 - 05/2009
2	Glucose (Dextrose)FDA LinkGeneric 01/2010 - 11/2006
2	CreatinineIBA 05/2009 - 12/2006
2	Digoxin (Digitek)FDA LinkGeneric 02/2009 - 12/2008
2	EtoricoxibIBA 12/2008 - 06/2008
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 03/2007 - 01/2002
1	Glutens (Glutelin)IBA 01/2021
1	Calcitonin Gene-Related PeptideIBA 01/2020
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2020
1	ubrogepantIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2018
1	grazoprevirIBA 01/2018
1	elbasvirIBA 01/2018
1	Apolipoproteins B (ApoB)IBA 01/2017
1	ApolipoproteinsIBA 01/2017
1	Hallucinogens (Psychedelics)IBA 08/2016
1	Zolpidem (Ambien)FDA LinkGeneric 08/2016
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 03/2016
1	EnzymesIBA 01/2016
1	Naloxone Drug Combination Buprenorphine FDA Link 03/2015
1	Methadone (Dolophine)FDA LinkGeneric 03/2015
1	Opioid Analgesics (Opioids)IBA 03/2015
1	GoldIBA 03/2015
1	MK-0888IBA 02/2015
1	ProdrugsIBA 11/2014
1	Sirolimus (Rapamycin)FDA Link 11/2014
1	Raloxifene Hydrochloride (Evista)FDA Link 09/2014
1	Paroxetine (Paxil)FDA LinkGeneric 09/2014
1	Adenosine Diphosphate (ADP)IBA 01/2014
1	CollagenIBA 01/2014

Therapy/Procedure

4	Therapeutics 09/2013 - 12/2009
1	Oral Administration 01/2018